Jensen Investment Management Inc. Takes $3.66 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Jensen Investment Management Inc. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 50,760 shares of the medical equipment provider’s stock, valued at approximately $3,659,000.

Other hedge funds have also recently modified their holdings of the company. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter valued at about $26,000. Groupama Asset Managment increased its holdings in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.0 %

Shares of NASDAQ:HOLX opened at $60.71 on Monday. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67. The firm has a market capitalization of $13.62 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business’s 50 day moving average price is $67.18 and its 200-day moving average price is $74.64.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.